experi
almost
year
ago
demonstr
inject
sequenc
dna
encod
part
pathogen
could
stimul
immun
soon
realiz
dna
vaccin
numer
potenti
advantag
convent
vaccin
approach
includ
inher
safeti
rapid
product
time
attribut
make
dna
vaccin
ideal
develop
emerg
pathogen
recent
advanc
optim
variou
aspect
dna
vaccin
acceler
approach
concept
realiti
contemporari
human
trial
although
yet
licens
human
use
sever
dna
vaccin
approv
anim
health
indic
rapid
manufactur
capabl
dna
vaccin
may
particularli
import
emerg
infecti
diseas
includ
current
novel
influenza
pandem
preexist
immun
limit
recent
advanc
dna
vaccin
approach
potenti
power
new
weapon
protect
emerg
potenti
pandem
human
pathogen
throughout
record
histori
infecti
diseas
plagu
human
exist
one
effect
approach
limit
diseas
vaccin
exampl
recent
report
roush
colleagu
us
center
diseas
control
prevent
cdc
ever
sinc
introduct
vaccin
incid
infecti
diseas
like
diphtheria
mump
pertussi
tetanu
hepat
b
haemophilu
influenza
varicella
zoster
declin
us
furthermor
introduct
vaccin
larg
scale
transmiss
measl
rubella
polio
elimin
us
smallpox
erad
worldwid
howev
new
emerg
infecti
pathogen
hiv
human
immunodefici
viru
sar
coronaviru
sever
acut
respiratori
syndrom
viru
highli
pathogen
avian
influenza
virus
adapt
strategi
rapidli
chang
genet
composit
influenza
pandem
kill
approxim
million
peopl
worldwid
massiv
diseas
death
similarli
fear
newli
emerg
pathogen
addit
current
novel
swine
deriv
pandem
exemplifi
need
rapid
effect
vaccin
emerg
pathogen
thu
vaccin
strategi
control
emerg
diseas
requir
effect
rapid
respons
avail
convent
approach
liveattenu
vaccin
inactiv
vaccin
protein
subunit
vaccin
plasmid
dna
vaccin
review
articl
may
option
effect
combat
current
emerg
infecti
diseas
almost
year
ago
malon
felgner
vical
incorpor
wolff
colleagu
univers
wisconsin
demonstr
mrna
close
loop
doublestrand
dna
plasmid
inject
muscl
tissu
could
taken
cell
administr
site
transfect
result
product
express
protein
normal
made
host
cell
soon
realiz
approach
could
util
gene
therapi
well
vaccin
applic
thu
field
dna
vaccin
born
shortli
origin
observ
mani
group
includ
led
liu
colleagu
merck
research
laboratori
weiner
colleagu
univers
pennsylvania
johnston
colleagu
univers
texa
robinson
colleagu
univers
massachusett
hoffman
colleagu
naval
medic
research
center
demonstr
immun
dna
could
result
product
foreign
protein
antigen
stimul
immun
system
result
protect
amelior
infecti
diseas
anim
model
develop
area
greatli
advanc
year
human
clinic
trial
dna
vaccin
conduct
variou
infecti
pathogen
includ
malaria
parasit
dengu
virus
cytomegaloviru
cmv
ebola
viru
season
influenza
virus
avian
pandem
influenza
virus
west
nile
viru
wmv
sar
coronaviru
hepat
b
viru
hiv
precis
mechan
induct
immun
pdna
vaccin
complex
multifactori
figur
thought
immun
transfect
muscl
cell
may
produc
antigen
foreign
protein
directli
stimul
b
cell
immun
system
turn
produc
antibodi
transfect
muscl
cell
could
possibl
transfer
antigen
socal
antigen
present
cell
demonstr
cross
prime
transport
protein
via
distinct
pathway
mhc
cell
mhc
ii
cell
result
display
differ
process
fragment
express
protein
antigen
final
direct
transfect
antigen
present
cell
dendrit
cell
subsequ
process
display
mhcantigen
complex
may
also
occur
process
antigen
product
host
cell
dna
vaccin
mimic
product
antigen
natur
infect
result
immun
respons
thought
similar
type
induc
pathogen
inde
dna
vaccin
gener
antigen
nativ
form
similar
structur
function
antigen
gener
natur
infect
plasmid
use
dna
vaccin
figur
contain
gene
encod
antigen
target
pathogen
immunogen
gene
express
protein
antigen
turn
host
cell
promot
turn
termin
polyadenyl
signal
sequenc
gener
refer
aspolya
gene
bacteri
origin
replic
sequenc
antibiot
resist
gene
incorpor
manufactur
purpos
result
plasmid
stabl
selfcontain
unit
manufactur
consist
scalabl
bacteri
ferment
purif
process
product
dna
vaccin
start
e
coli
cell
transform
plasmid
interest
cell
grown
store
frozen
stock
vial
call
master
cell
bank
growth
e
coli
typic
done
via
ferment
process
similar
use
manufactur
certain
alcohol
beverag
recoveri
process
requir
lysi
cell
order
releas
plasmid
retain
within
e
coli
cell
dna
purifi
use
variou
chromatograph
method
dna
vaccin
mani
advantag
compar
convent
vaccin
approach
appendix
particularli
set
protect
potenti
lethal
emerg
infecti
diseas
protect
particular
pathogen
may
requir
immun
one
compon
organ
may
requir
stimul
differ
compon
host
immun
system
tradit
prevent
vaccin
reli
antibodi
main
correl
protect
compon
prevent
infect
diseas
howev
cell
play
import
role
control
diseas
establish
infect
convent
vaccin
base
whole
pathogen
typic
induc
immun
respons
number
irrelev
compon
organ
subunit
protein
vaccin
target
individu
compon
pathogen
usual
stimul
antibodi
dna
vaccin
accommod
combin
differ
gene
code
differ
antigen
one
differ
pathogen
result
gener
broad
immun
multipl
protein
antigen
dna
vaccin
also
observ
stimul
antibodi
cell
arm
immun
system
includ
special
kill
virus
cancer
cell
via
cytotox
killer
cell
signific
advantag
especi
emerg
pathogen
dna
vaccin
requir
handl
potenti
deadli
infecti
agent
addit
significantli
shorter
product
time
someth
paramounrt
ongo
pandem
overal
welltoler
safeti
profil
observ
human
clinic
trial
dna
vaccin
earli
develop
numer
theoret
safeti
concern
regard
dna
vaccin
particular
concern
fate
inject
gene
potenti
insert
host
dna
possibl
result
ing
uncontrol
stimul
gene
may
caus
cancer
concern
dissip
year
base
thousand
human
subject
undergon
dna
vaccin
plasmidbas
gene
therapi
furthermor
preclin
safeti
studi
anim
potenti
plasmid
integr
host
genom
shown
neglig
sever
order
magnitud
spontan
mutat
rate
occur
natur
mammalian
gene
also
earli
concern
regard
induct
autoimmun
reaction
dna
may
consid
self
antigen
host
increas
rate
autoimmun
antidna
antibodi
observ
system
lupu
erythematosi
observ
clinic
trial
dna
vaccin
interestingli
plasmid
dna
vaccin
noninfecti
signific
immun
respons
develop
plasmid
therefor
specif
immun
respons
express
antigen
stimul
approach
contrast
viral
vector
adenovirus
preexist
post
vaccin
immun
vector
gener
therebi
limit
pathogen
specif
immun
respons
contrast
dna
vaccin
repeat
without
diminish
specif
immun
respons
may
pertin
benefici
aspect
dna
immun
particularli
light
recent
clinic
trial
human
use
viral
vectorbas
vaccin
common
cold
adenoviru
immun
vector
rais
potenti
safeti
issu
summari
potenti
risk
dna
vaccin
appear
minim
base
safeti
data
human
clinic
trial
thousand
subject
year
much
progress
made
optim
dna
vaccin
immunogen
recent
progress
target
mani
differ
aspect
dna
vaccin
success
result
improv
immun
respons
appendix
regard
plasmid
signific
advanc
made
optim
genet
sequenc
encod
gene
well
relat
compon
coadministr
plasmid
encod
pathogen
along
gene
encod
immun
stimul
substanc
cytokin
chemokin
also
use
enhanc
immun
respons
certain
dna
vaccin
case
variou
compon
plasmid
optim
encod
protein
may
suffici
immunogen
without
need
addit
compon
unformul
nake
dna
adjuv
one
earliest
trial
human
unformul
nake
dna
vaccin
one
target
malaria
parasit
wang
colleagu
naval
medic
research
institut
immun
subject
plasmid
encod
natur
occur
form
malaria
protein
trial
half
subject
shown
cell
kill
lyse
malaria
infect
cell
cytotox
cell
killer
cell
recent
clinic
trial
dna
vaccin
optim
human
express
encod
modifi
form
west
nile
viru
protein
studi
martin
colleagu
nation
institut
health
nih
demonstr
vaccin
stimul
antibodi
inhibit
viru
neutral
antibodi
individu
receiv
vaccin
regimen
unformul
dna
vaccin
appear
induc
similar
level
immun
respons
observ
vaccin
hors
protect
wnv
addit
recent
clinic
trial
nih
research
test
optim
unformul
dna
vaccin
sar
coronaviru
demonstr
neutral
antibodi
subject
receiv
three
dose
vaccin
anoth
area
research
enhanc
immun
respons
dna
vaccin
relat
rout
administr
although
intramuscular
inject
predomin
rout
vaccin
deliveri
rout
administr
also
studi
intraderm
deliveri
conceiv
intraderm
deliveri
superfici
inject
may
result
better
transfect
antigen
present
cell
particularli
type
cell
call
dendrit
cell
mode
deliveri
may
also
pertin
factor
elicit
proper
immun
respons
dna
immun
needl
syring
predomin
method
deliv
dna
vaccin
well
convent
vaccin
howev
roy
colleagu
powderm
pfizer
incorpor
use
dna
precipit
onto
gold
particl
driven
skin
blast
pressur
ga
call
approach
particlemedi
epiderm
deliveri
pmed
one
clinic
studi
roy
collabor
use
pmed
individu
exhibit
potent
antibodi
respons
hepat
b
dna
vaccin
anoth
studi
drape
colleagu
powderm
also
observ
strong
antibodi
respons
influenza
viru
dna
vaccin
pmed
approach
anoth
approach
deliveri
dna
vaccin
use
needlefre
devic
needlefre
inject
dna
vaccin
util
numer
clinic
studi
appear
welltoler
may
advantag
augment
immun
respons
dna
vaccin
exampl
nabel
colleagu
nih
inject
individu
intramuscularli
sixplasmid
unformul
dna
vaccin
hiv
env
env
b
env
c
subtyp
b
gag
pol
nef
needlefre
devic
biojector
observ
hiv
specif
tcell
immun
respons
individu
similarli
group
nih
complet
recent
studi
ebola
dna
vaccin
also
use
needlefre
devic
demonstr
ebolaspecif
antibodi
tcell
immun
respons
elicit
individu
receiv
threedos
vaccin
regimen
anoth
novel
mode
enhanc
dna
vaccin
invas
techniqu
call
electropor
method
involv
administr
brief
electr
puls
variou
voltag
inject
dna
vaccin
order
enhanc
uptak
dna
presum
format
transient
pore
muscl
cell
membran
mani
group
shown
encourag
result
use
electropor
anim
one
first
group
use
techniqu
ulmer
colleagu
chiron
corpor
demonstr
antibodi
tcell
respons
hiv
protein
gag
encod
dna
vaccin
enhanc
electropor
rhesu
macaqu
recent
studi
pavlaki
colleagu
nih
also
note
dna
potenc
measur
tcell
respons
hiv
protein
gag
augment
nonhuman
primat
use
electropor
although
encourag
strong
magnitud
respons
gener
anim
wide
clinic
applic
electropor
human
relat
toler
remain
determin
research
use
plasmid
dna
call
heterolog
primeboost
vaccin
approach
method
involv
deliveri
one
plasmid
dna
vaccin
prime
dose
follow
boost
viral
vector
adenoviru
code
antigen
primeboost
set
dna
vaccin
play
import
role
prime
differ
type
tcell
tcell
specif
variou
protein
studi
exampl
nabel
colleagu
nih
dna
vaccin
plasmid
encod
hiv
antigen
follow
boost
adenovir
vector
carri
hiv
gene
sequenc
result
stronger
tcell
respons
compar
adenovir
vector
dna
vaccin
alon
similarli
pantaleo
colleagu
univers
lausann
shown
dna
vaccin
hiv
follow
boost
poxviru
vector
nyvac
result
stronger
immun
respons
compar
immun
pox
vector
alon
anoth
primeboost
studi
jacobson
colleagu
univers
california
san
francisco
immun
subject
dna
vaccin
cmv
boost
liveattenu
cmv
viru
town
strain
faster
stronger
virusspecif
tcell
respons
observ
group
subject
receiv
dna
town
strain
compar
group
subject
receiv
town
strain
alon
area
potenti
paramount
import
dna
vaccin
formul
adjuv
adjuv
common
licens
vaccin
includ
potenti
immun
respons
elicit
vaccin
dna
vaccin
variou
deliveri
system
adjuv
test
one
earliest
promis
adjuv
plasmid
dna
vaccin
polylactid
coglycolid
plg
cation
microparticl
ulmer
colleagu
chiron
corpor
evalu
hiv
dna
vaccin
formul
plg
microparticl
found
strong
antibodi
tcell
respons
macaqu
poloxam
repres
anoth
class
adjuv
test
dna
vaccin
poloxam
nonion
block
copolym
combin
cation
surfact
bond
dna
form
small
particl
studi
wloch
colleagu
vical
incorpor
examin
dna
immun
human
volunt
cytomegaloviru
cmv
plasmid
formul
specif
poloxam
adjuv
studi
cmvspecif
tcell
respons
detect
major
cmv
seroneg
individu
vaccin
vaxfectin
anoth
exampl
deliveri
system
adjuv
dna
vaccin
recent
test
human
vaxfectin
cation
lipidbas
adjuv
bear
posit
charg
bind
electrostat
neg
charg
dna
studi
anim
also
demonstr
vaxfectin
adjuv
dna
vaccin
protect
lethal
viral
challeng
exampl
webbi
colleagu
st
jude
children
research
hospit
vical
incorpor
immun
ferret
three
plasmid
contain
dna
compon
pandem
influenza
viru
formul
vaxfectin
one
two
immun
anim
complet
protect
lethal
pandem
influenza
viru
challeng
unvaccin
control
anim
die
similarli
griffin
colleagu
john
hopkin
immun
juvenil
infant
rhesu
macaqu
intramuscular
intraderm
rout
measl
antigen
encod
plasmid
formul
vaxfectin
vaccin
monkey
develop
strong
durabl
neutral
antibodi
challeng
high
dose
measl
viru
one
year
unvaccin
control
anim
develop
viremia
becam
ill
rash
contrast
vaccin
anim
remain
healthi
detect
viru
level
lastli
first
human
clinic
trial
dna
vaccin
formul
vaxfectin
complet
plasmid
encod
pandem
influenza
viru
antigen
preliminari
result
report
trial
smith
colleagu
vical
incorpor
suggest
vaccin
dna
plasmid
formul
adjuv
welltoler
stimul
strong
antibodi
respons
subject
notabl
antibodi
respons
rate
safeti
profil
observ
trial
compar
convent
proteinbas
vaccin
pandem
influenza
although
dna
vaccin
yet
approv
human
use
three
alreadi
approv
anim
health
note
appendix
first
dna
vaccin
approv
anim
health
one
protect
hors
wnv
wnv
mosquitoborn
viru
caus
enceph
inflamm
brain
infect
anim
human
prior
approv
vaccin
approxim
onethird
hors
infect
wnv
would
die
euthan
wnv
dna
vaccin
develop
fort
dodg
laboratori
approv
us
depart
agricultur
usda
demonstr
safeti
efficaci
dna
vaccin
also
recent
approv
prevent
fatal
viral
diseas
afflict
salmon
call
infecti
hematopoiet
necrosi
viru
epidem
occur
atlant
salmon
kill
fish
scientist
aqua
health
unit
novarti
canada
conduct
field
trial
immun
million
salmon
singl
dose
dna
vaccin
encod
protein
viru
vaccin
approv
base
result
trial
demonstr
vaccin
call
apexihn
protect
fish
death
without
advers
effect
addit
therapeut
dna
vaccin
design
treat
dog
skin
cancer
melanoma
grant
condit
approv
vaccin
develop
collabor
memori
sloankett
cancer
center
mskcc
merial
ltd
canin
melanoma
aggress
form
cancer
dog
melanoma
gone
beyond
initi
stage
typic
lifespan
one
five
month
convent
therapi
addit
cancer
often
resist
chemotherapi
studi
dna
vaccin
conduct
mskcc
mani
dog
receiv
vaccin
live
beyond
averag
month
surviv
base
significantli
extend
surviv
usda
gave
dna
vaccin
condit
approv
first
therapeut
vaccin
approv
us
govern
treatment
cancer
anim
human
perhap
relev
emerg
infecti
diseas
dna
vaccin
distinct
advantag
rapid
develop
time
noninfecti
welldefin
manufactur
process
dna
vaccin
contain
infecti
compon
produc
safe
without
handl
hazard
infecti
agent
furthermor
welldefin
analyt
process
manufactur
dna
vaccin
univers
applic
dna
vaccin
vaccin
import
compon
respons
potenti
pandem
avian
influenza
accord
world
health
organ
sinc
novemb
approxim
case
human
infect
highli
pathogen
avian
influenza
report
worldwid
pandem
influenza
viru
evolv
least
distinct
clade
subclad
note
earlier
emerg
triplereassort
swine
influenza
limit
cross
reactiv
antibodi
respons
vaccin
season
influenza
vaccin
suggest
need
rapidli
produc
new
vaccin
particular
emerg
viru
manufactur
time
convent
proteinbas
vaccin
may
excess
typic
requir
growth
egg
cell
cultur
involv
rel
slow
product
time
dna
vaccin
contrast
estim
vaccin
product
time
month
earlier
dna
sequenc
requir
manufactur
process
standard
figur
dna
vaccin
therefor
uniqu
advantag
larg
scale
product
human
use
rel
streamlin
period
time
case
potenti
fatal
emerg
pathogen
reduc
product
time
effect
vaccin
may
critic
prevent
spread
infect
death
summari
base
recent
advanc
enhanc
protect
immun
respons
welltoler
safeti
profil
human
plasmid
dna
vaccin
potenti
becom
integr
part
arsen
dedic
enhanc
human
health
prevent
diseas
immun
ever
chang
microbi
environ
author
declar
compet
interest
abil
immun
multipl
antigen
andor
pathogen
